MARKET

CBAY

CBAY

CymaBay
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.220
-0.050
-1.17%
Pre Market: 4.220 0 0.00% 08:19 05/06 EDT
OPEN
4.280
PREV CLOSE
4.270
HIGH
4.330
LOW
4.150
VOLUME
22
TURNOVER
--
52 WEEK HIGH
9.06
52 WEEK LOW
1.740
MARKET CAP
290.96M
P/E (TTM)
-5.7019
1D
5D
1M
3M
1Y
5Y
10 “Strong Buy” Healthcare Stocks With Over 100% Upside Potential According to Top Analysts
TipRanks.com · 04/27 13:58
Primary Biliary Cirrhosis Drug Market 2021 Research and Clinical Analysis- AlbireoPharma (NASDAQ: LBO), CymaBay Therapeutics, MediGene AG, NGM Biopharmaceuticals
Apr 26, 2021 (Market Insight Reports) -- Global Primary Biliary Cirrhosis Drug Market Size, Status and Forecast 2021 The Global Primary Biliary Cirrhosis...
Market Insight Reports · 04/26 09:54
XM, IRDM, EOLS and AZN among after-hours movers
Gainers: [[XM]] +7.9%. [[CHDN]] +6.0%. [[IRDM]] +4.8%. [[UFPI]] +4.8%. [[SYBX]] +4.4%.Losers: [[EOLS]] -13.7%. [[AZN]] -7.9%. [[CBAY]] -6.6%. [[SNBR]] -6.0%. [[CENX]] -5.7%.
Seekingalpha · 04/21 21:30
Glucose Dependent Insulinotropic Receptor Market 2021 by Product Type, With Sales, Revenue, Price, Market Share and Growth Rate by 2027
The Express Wire · 04/21 10:44
Global Primary Biliary Cirrhosis Drug Market Insights, Overview, Analysis and Forecast 2021-2026
Apr 20, 2021 (Heraldkeepers) -- The Primary Biliary Cirrhosis Drug market report provides a detailed analysis of global market size, regional and...
Heraldkeepers · 04/20 08:25
Global Homozygous Familial Hypercholesterolemia Treatment Market Outlook, Industry Analysis and Prospect 2021-2026
Apr 15, 2021 (Heraldkeepers) -- COMTEX_384481072/2582/2021-04-15T07:59:11 Is there a problem with this press release? Contact the source provider Comtex at...
Heraldkeepers · 04/15 11:59
Global Hypertriglyceridemia Treatment Market Size, Share, Value, and Competitive Landscape 2024 .
Apr 15, 2021 (Heraldkeepers) -- Research ScopeThis report researches the worldwide Hypertriglyceridemia Treatment market size (value) in key regions like...
Heraldkeepers · 04/15 05:32
Gout Disease Treatment Market Report Released Forecasting Movement in the Industry
Apr 14, 2021 (Market Insight Reports) -- Global Gout Disease Treatment Market Gout is a severe medical condition characterized by formation of excess of uric...
Market Insight Reports · 04/14 11:20
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CBAY. Analyze the recent business situations of CymaBay through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CBAY stock price target is 12.00 with a high estimate of 15.00 and a low estimate of 7.00.
EPS
Institutional Holdings
Institutions: 222
Institutional Holdings: 69.37M
% Owned: 100.61%
Shares Outstanding: 68.95M
TypeInstitutionsShares
Increased
41
4.85M
New
46
3.58M
Decreased
36
6.57M
Sold Out
20
3.54M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.92%
Pharmaceuticals & Medical Research
+0.20%
Key Executives
Non-Executive Chairman/Independent Director
Robert Wills
President/Chief Executive Officer/Director/IR Contact Officer
Sujal Shah
Senior Vice President/Chief Scientific Officer
Charles McWherter
Chief Compliance Officer
Klara Dickinson
Vice President - Finance
Daniel Menold
Director
Janet Dorling
Director
Thomas Wiggans
Independent Director
Caroline Loewy
Independent Director
Kurt von Emster
No Data
About CBAY
CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. Its pipeline includes Seladelpar, MBX-2982 and CB-001. The Company’s lead product candidate, seladelpar, is a potent and selective agonist of peroxisome proliferator-activated receptor delta (PPARd), a nuclear receptor that regulates genes directly or indirectly involved in the synthesis of bile acids/sterols, metabolism of lipids and glucose, inflammation and fibrosis. The PPARd receptor is a nuclear receptor that regulates genes involved in bile acid/sterol, lipid, and glucose metabolism, and regulation of certain inflammatory cells. Seladelpar focuses on treating certain diseases of the liver and a variety of disorders of lipid metabolism.

Webull offers kinds of CymaBay Therapeutics Inc stock information, including NASDAQ:CBAY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CBAY stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CBAY stock methods without spending real money on the virtual paper trading platform.